Annual report pursuant to Section 13 and 15(d)

Consolidated Statements Of Cash Flows

v2.4.0.6
Consolidated Statements Of Cash Flows (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Cash flows from operating activities:      
Net loss $ (15,203) $ (6,834) $ (5,886)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 32 85 169
Amortization of discount on long-term debt 1,520 132  
Interest on royalty liability 1,309    
Non-cash gain on decrease in fair value of warrants (1,862)    
Gain on investments     (9)
Gain on disposition of property and equipment     3
Stock-based compensation 1,177 733 1,523
Changes in operating assets and liabilities:      
Receivables (2,495) (1,159)  
Prepaid expenses and other current assets (542) (44) 405
Accounts payable 2,332 2,122 (158)
Accrued clinical trials and other liabilities (744) 308 (1,454)
Net cash used in operating activities (14,476) (4,657) (5,407)
Cash flows from investing activities:      
Purchases of property and equipment (236) (28) (7)
Disposals of property and equipment 2    
Proceeds from the sale of investments     9
Net cash (used in) provided by investing activities (234) (28) 2
Cash flows from financing activities:      
Proceeds from issuance of common stock from private placement     478
Proceeds from issuance of common stock from exercise of stock options     555
Proceeds from royalty financing 8,000    
Net proceeds from long-term debt 16,500 5,000 3,000
Payments on long-term debt (7,564) (435)  
Net cash provided by financing activities 16,936 4,565 4,033
Net increase (decrease) in cash 2,226 (120) (1,372)
Cash at beginning of period 3,180 3,300 4,672
Cash at end of period 5,406 3,180 3,300
Supplemental disclosure of cash flow information      
Interest paid 1,652 678 9
Schedule of non-cash transactions      
Retirement of preferred stock upon dissolution of Ingenex, Inc.   $ 1,241